Search

Your search keyword '"Bernard Milleron"' showing total 225 results

Search Constraints

Start Over You searched for: Author "Bernard Milleron" Remove constraint Author: "Bernard Milleron"
225 results on '"Bernard Milleron"'

Search Results

1. Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)

2. Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study

3. Supplementary Methods, Figures 1-2, Figure 4, Tables 1-5 from An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial

4. Acknowledgements List from An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial

5. Supplementary Table 3 from An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial

6. Data from An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial

8. Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)

9. Intergroupe francophone de cancérologie thoracique, Société de pneumologie de langue française, and Société d’imagerie thoracique statement paper on lung cancer screening

10. Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial

11. Availability of results of academic randomized trials involving cooperative groups in oncology in France: A systematic search of clinical trial registries

12. Results of Second Round Lung Cancer Screening by Low-Dose CT scan - French Cohort Study (DEP-KP80)

13. Inhibiteurs du check-point immunitaire en néo-adjuvant dans les cancers bronchiques non à petites cellules localisés : essai IoNESCO

14. [Lung cancer screening, what methods what results ?]

16. Potential lung cancer screening outcomes using different age and smoking thresholds in the ANRS-CO4 French Hospital Database on HIV cohort

17. Les traitements péri-opératoires des cancers bronchiques non à petites cellules (CNPC) : standards actuels et perspectives

18. Activité de recherche clinique académique des investigateurs du réseau des Groupes coopérateurs en oncologie (GCO) : bilan et perspectives

19. Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial

20. Le dépistage du cancer du poumon

21. Lung Cancer Screening by Low-Dose CT Scan: Baseline Results of a French Prospective Study

22. Immunothérapie (durvalumab) néoadjuvante dans les cancers bronchiques non à petites cellules (CBNPC) : Résultats préliminaires de l’étude multicentrique IFCT-1601 IONESCO

23. Lung Cancer Screening with Chest Computed Tomography in People Living with HIV: A Review by the Multidisciplinary CANCERVIH Working Group

24. Évaluation des connaissances sur le dépistage du cancer par test de concordance de script

25. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

26. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

27. Lung cancer screening: what is new since the NLST results?

28. La réponse complète histologique : un facteur prédictif de survie après chimiothérapie néoadjuvante dans le cancer bronchopulmonaire

29. Faut-il implanter le dépistage du cancer bronchique dans notre pays et à quelles conditions ?

30. Surveillance après traitement local ou loco-régional optimal

31. 1214O Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): Preliminary results from a multicenter study (IFCT-1601 IONESCO)

32. Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301)

33. [Clinical research activity of the French cancer cooperative network: Overview and perspectives]

34. Maladie oligométastatique dans le cancer bronchique non à petites cellules

35. 2014 update on non-small cell lung cancer (excluding diagnosis)

36. Second-line therapy in elderly patients with advanced nonsmall cell lung cancer

37. Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy

38. Le dépistage scanographique du cancer bronchopulmonaire

39. Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer

41. Lung cancer in never smokers – A review

42. Concurrent chemoradiation for elderly patients with locally advanced non-small-cell lung cancer: still a controversial issue

43. Factors associated with long-term survival of patients with advanced non-small cell lung cancer

44. Skin Toxicities Compromise Prolonged Pemetrexed Treatment

45. Protocole IFCT 0803 – Étude de phase II évaluant l’association de cétuximab à une radiothérapie et chimiothérapie concomitante par cisplatine et pémétrexed dans le traitement des cancers bronchiques non à petites cellules non épidermoïdes de stade III, inopérables

46. Dépistage du cancer du poumon

47. Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study)

48. Fibrose et hypertension artérielle pulmonaires révélant un poumon bilharzien chronique. Un diagnostic inhabituel en Europe

49. Hémoptysies graves des cancers bronchiques

50. Place des traitements adjuvants et néo-adjuvants dans les cancers non à petites cellules (CBNPC) de stade précoce

Catalog

Books, media, physical & digital resources